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Abstract
Background Hyper- and hyponatremia are frequently
observed in patients after subarachnoidal hemorrhage, and
are potentially related to worse outcome. We hypothesized
that the fluid regimen in these patients is associated with
distinct changes in serum electrolytes, acid–base distur-
bances, and fluid balance.
Methods Thirty-six consecutive patients with SAH were
randomized double-blinded to either normal saline and
hydroxyethyl starch dissolved in normal saline (Voluven;
saline) or balanced crystalloid and colloid solutions (Rin-
gerfundin and Tetraspan; balanced, n = 18, each) for
48 h. Laboratory samples and fluid balance were evaluated
at baseline and at 24 and 48 h.
Results Age [57 ± 13 years (mean ± SD; saline) vs.
56 ± 12 years (balanced)], SAPS II (38 ± 16 vs. 34 ± 17),
Hunt and Hess [3 (1–4) (median, range) vs. 2 (1–4)], and
Fischer scores [3.5 (1–4) vs. 3.5 (1–4)] were similar. Serum
sodium, chloride, and osmolality increased in saline only
(p B 0.010, time–group interaction). More patients in saline
had Cl >108 mmol/L [16 (89 %) vs. 8 (44 %); p = 0.006],
serum osmolality >300 mosmol/L [10 (56 %) vs. 2 (11 %);
p = 0.012], a base excess <-2 [12 (67 %) vs. 2 (11 %);
p = 0.001], and fluid balance >1,500 mL during the first
24 h [11 (61 %) vs. 5 (28 %); p = 0.046]. Hyponatremia
and hypo-osmolality were not more frequent in the balanced
group.
Conclusions Treatment with saline-based fluids resulted
in a greater number of patients with hyperchloremia,
hyperosmolality, and positive fluid balance >1,500 mL
early after SAH, while administration of balanced solutions
did not cause more frequent hyponatremia or hypo-osmo-
lality. These results should be confirmed in larger studies.
Keywords Subarachnoid hemorrhage  Fluid therapy 
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Introduction
Serum sodium concentration and fluid balance are frequently
abnormal in patients after subarachnoid hemorrhage (SAH)
[1, 2], with dysnatremia causing morbidity in patients with
SAH [3–5]. Moreover, in other critically ill or emergency
patient populations, both severe hyper- and hyponatremia are
associated with persistent neurological deficits and high
mortality [6–8]. Traditionally, patients with cerebral insults
receive sodium chloride containing fluids (normal saline) for
baseline and substitution requirements. The rationale for this
approach is to avoid fluid shifts across a damaged blood–brain
barrier and subsequent brain edema, both of which can occur
if more physiological, slightly hypoosmolar types of fluids are
used [9, 10]. Nevertheless, this has never been shown in
patients after SAH. In addition, normal saline has been
associated with metabolic acidosis and slower urinary output
in volunteers [11] and with metabolic acidosis and hyperka-
lemia in patients undergoing kidney transplantation [12]
compared with lactated Ringer’s solutions. On the other hand,
balanced IV solutions were able to prevent the development of
hyperchloremic metabolic acidosis, and provided better gas-
tric mucosal perfusion compared with saline-based fluids in
elderly surgical patients [13].
The infusion of saline increases natriuresis and conse-
quently water diuresis. However, expanding the
extracellular volume by sodium administration may also
cause tissue edema. Consequently, liberal administration of
saline and saline-based colloids may contribute to a dis-
equilibrium in salt and water balance, and ultimately to
morbidity in these patients.
The aim of this hypothesis-generating study was to
evaluate the physiology of electrolyte and water homeo-
stasis in patients after SAH using two different blinded
fluid regimens. We hypothesized that an approach with
saline-based fluids would result in hypernatremia, hyper-
chloremia, and hyperchloremic metabolic acidosis, with
more frequent serum hyper-osmolality and less well-
maintained fluid balance compared to a regimen with a
more physiological fluid composition. Since prediction of
the magnitude of the postulated effects was difficult, we
chose to randomize the patients to the treatment for only
2 days.
Methods
The study was approved by the Ethics Committee of the
Canton of Bern, Switzerland. Inclusion and exclusion
criteria were evaluated by an independent physician prior
to study start, and deferred written informed consent
was obtained from a close family member within 48 h
after admission to the intensive care unit. A previous study
including 36 volunteers assigned to saline versus balanced
infusion reported significant differences in pH, serum
osmolality, and sodium concentration [11]. Accordingly, we
aimed to include 18 patients per group. Consecutive emer-
gency patients >18 years with a history of SAH were
included. Patients were treated according to the standard
clinical procedure at the Bern University Hospital, which
included early surgical or endovascular intervention and the
use of nimodipine. Blood pressure was kept low before the
intervention (clipping or coiling; systolic blood pressure
100–120 mmHg) and normal to slightly elevated afterward
(120–160 mmHg). The baseline fluid administration rate
was 1.5 mL/kg/h, and substitution was performed with
crystalloids and colloids at approximately a 1:1 ratio when
clinical signs of hypovolemia developed (low blood pres-
sure and/or low urinary output [<0.5 mL/kg/h] in the
presence of low peripheral skin temperature, and/or
decreased capillary refill or central/peripheral venous fill-
ing). Baseline fluid rate was increased if the prescribed
hemodynamic goals were not achieved despite several vol-
ume challenges, and decreased if clinical or radiological
signs of fluid overload developed. The clinical status of the
patients was continually observed by the treating nurse, and
hemodynamic and clinical parameters recorded and dis-
played in a patients data management system (Clinisoft, GE,
Helsinki, Finland). This system displays trends over time of
each registered parameter which facilitates the interpretation
of hemodynamic status evolution. Each patient was visited
at least once every 8 h by the treating physician, and twice
daily by a research nurse. At ICU admission, patients were
randomized to a blinded volume regimen with either normal
saline and hydroxyethyl starch dissolved in normal saline
(Voluven, Fresenius Kabi AG, Bad Homburg, Germany)
or balanced crystalloid and colloid solutions (Ringerfundin
and Tetraspan, B. Braun Medical AG, Sempach, Switzer-
land). The composition of the different fluids is displayed in
Table S1 of the electronic supplement. Fluids were prepared
by non-blinded nurses who were not involved in the treat-
ment of the patients. Fluid bags were wrapped in opaque
plastic bags and labeled as ‘‘crystalloid’’ or ‘‘colloid’’ to
ensure blinding. The randomized treatment was continued
for 48 h.
The following parameters were measured and evaluated
at baseline and at 24 and 48 h: serum sodium, potassium,
chloride, osmolality, glucose, creatinine, troponine, TSH,
fT3, fT4, and plasma cortisol, and urine sodium, potassium,
chloride, osmolality, and creatinine. Total fluid and sodium
balances were measured and osmolar and free water
clearances were calculated at 24-h intervals. The balances
included baseline fluids, fluids administered to achieve the
prescribed hemodynamic goals, enteral nutrition, and all
fluids administered with drugs delivered as infusions or by
syringe pumps.
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For the assessment of neurological outcome, the modi-
fied Rankin scale was used [14]. The modified Rankin
Scale is commonly used for measuring the degree of dis-
ability or dependence in the performance of daily activities.
It ranges from 0 (perfect health without symptoms) to 6
(death).
Statistical Analysis
The SPSS 16.0 software package (SPSS Inc., Chicago,
IL, USA) was used for statistical analysis, and statistical
significance was considered at p < 0.05. Normal dis-
tribution was assessed by the Kolmogorov–Smirnov test.
For variables with repeated measurements, differences
between groups were assessed by analysis of variance
using one dependent variable, one between-subject fac-
tor (saline vs. balanced), and one within-subject factor
(time). For non-normally distributed data, non-paramet-
ric ANOVA for repeated measurements (Friedman Test)
was used separately in both groups after comparison of
baseline data with the Mann–Whitney U test. Since 10
out of the 36 patients stayed less than two full days in
the ICU, baseline and 24-h measurements were primar-
ily included in ANOVA, followed by comparisons
between 24- and 48-h measurement in each group sep-
arately (paired t test or Wilcoxon test). Variables
assessed only twice (fluid balances and diuresis) were
compared between groups using unpaired t tests at each
time point. Categorical data were assessed using Fish-
er’s exact test. Data are reported as mean ± SD or as
median (range).
Results
18 patients were randomized to sodium-based fluid treat-
ment (group sodium) and 18 patients to balance-based fluid
treatment (group balanced). Demographic and severity-of-
illness data are displayed in Table 1. The incidence of
specific comorbidities other than arterial hypertension was
<15 % in each group. Three patients in the saline group
and seven patients in the balanced group stayed less than
48 h in the ICU.
There were no differences in the use of norepinephrine
(n = 5 in group saline vs. n = 6 in group balanced), cor-
ticosteroids (n = 11 in group saline vs. n = 6 in group
balanced), opioids, or antibiotics between the study groups.
Fluid and electrolyte administration and balances during
the first 24 h and from 24 to 48 h are indicated in Table 2.
Included in the administered fluids were also fluids given in
attempting to reach the prescribed hemodynamic goals
[1,090 ± 1,450 mL (first 24 h), and 680 ± 1,210 mL
(from 24 to 48 h; saline group), and 750 ± 1,170 mL
(first 24 h), and 870 ± 1,760 mL (from 24 to 48 h; balance
group), respectively (NS)]. While the variables were sim-
ilar in the two groups, sodium input was significantly
higher than sodium excretion during the first 24 h in the
saline group [592 ± 334 vs. 206 ± 177 mmol (n = 12);
Table 1 Demographic data
Saline group
(N = 18)
Balanced group
(N = 18)
Age (years) 57 ± 14 56 ± 12
Male/female 6/12 6/12
SAPS II 38 ± 16 34 ± 17
Admission GCS 11 (4–15) 12 (7–15)
Hunt and Hess grade 3 (1–4) 3 (1–4)
Hunt and Hess grade 3 or 4 10 7
Fischer score 3 (1–4) 3 (1–4)
History of art. hypertension 9 8
Mechanical ventilation 10 8
Troponin I (ng/mL) 1.5 (0.00–0.11)
(N = 7)
0 (0–3.15)
(N = 11)
SAPS simplified acute physiology score, GCS Glasgow Coma Scale
Table 2 Administered fluids and electrolytes, diuresis, and fluid
balance
Saline group Balanced group
Baseline to 24 h N = 18 N = 18
Baseline to 48 h N = 15
(mean ± SD)
N = 11
(mean ± SD)
Crystalloids (mL)
Baseline to 24 h 2,320 ± 1,400 2,250 ± 730
Baseline to 48 h 4,320 ± 1,640 4,500 ± 2,300
Colloids (mL)
Baseline to 24 h 1,750 ± 1,370 1,320 ± 1,060
Baseline to 48 h 3,030 ± 1,620 3,190 ± 2,190
Sodium administered (mmol)
Baseline to 24 h 626 ± 348 541 ± 228
Baseline to 48 h 1,136 ± 387 1,153 ± 657
Chloride administered (mmol)
Baseline to 24 h 624 ± 348 468 ± 189
Baseline to 48 h 1,129 ± 387 979 ± 552
Total fluid input (mL)
Baseline to 24 h 4,240 ± 2,360 4,160 ± 1,850
Baseline to 48 h 7,800 ± 2,750 9,420 ± 5,090
Diuresis (mL)
Baseline to 24 h 2,160 ± 950 3,220 ± 2,090
Baseline to 48 h 4,740 ± 2,230 5,960 ± 4,180
Fluid balance (mL)
Baseline to 24 h 2,090 ± 2,190 940 ± 2,130
Baseline to 48 h 3,260 ± 3,020 3,780 ± 4,940
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p = 0.005), but not in the balanced group (496 ± 246 vs.
334 ± 307 mmol (n = 9); n.s.]. A fluid balance of
>1,500 mL during the first 24 h was more frequent in
patients in the saline group [11 (61 %) vs. 5 (28 %);
p = 0.046].
Patients with SAH Hunt and Hess grade 3 and 4 had
higher fluid balances than patients with scores 1 and 2 (day
1: 2,360 ± 2,060 vs. 660 ± 2,120 mL/day; p = 0.02; day
2: 4,750 ± 4,250 vs. 1,500 ± 2,360 mL/day; p = 0.03).
The differences of fluid input and diuresis between the two
groups did not reach statistical significance. There was no
association between fluid balance and a history of hyper-
tension, corticosteroid or norepinephrine use, or serum
concentrations of cortisol, TSH, fT3, and fT4.
Hemodynamic and intracranial pressure values are
indicated in Table 3. Apart from a lower CVP in the bal-
anced group at 24 h, there were no differences between
groups.
Changes in serum sodium, chloride, and osmolality over
time are indicated in Figs. 1, 2 and 3. All variables increased
in the saline group and remained unchanged in the balanced
group (time–group interaction, all p B 0.010). Hyponatre-
mia (serum sodium <135 mmol/L) occurred in two patients
in the saline group and in none in the balanced group. More
patients in the saline group experienced hyperchloremia
[Cl > 108 mmol/L; 16 (89 %) vs. 8 (44 %); p = 0.006].
Serum hyper-osmolality (>300 mosmol/L) occurred in 10
(56 %) vs. 2 (11 %) patients (p = 0.012), and hypo-osmo-
lality (<285 mosmol/L) in 4 (22 %) vs. 6 (33 %; NS)
patients in saline versus balanced groups. During the first
Table 3 Time course of hemodynamics and intracranial pressure
Saline group Balanced
group
Test, p value
N baseline (hemodyn/ICP) 18/12 18/8
N 24 h (hemodyn/ICP) 18/13 18/9
N 48 h (hemodyn/ICP) 11/12 13/10
Systolic art. pressure (mmHg)
Baseline 129 ± 23 136 ± 25
24 h 135 ± 22 141 ± 20
48 h 135 ± 15 145 ± 17
Heart rate (beats/min)
Baseline 73 ± 16 71 ± 12
24 h 72 ± 11 73 ± 12
48 h 73 ± 13 71 ± 10
Central venous pressure (mmHg)
Baseline 7 ± 4 8 ± 5 TG, 0.002
24 h 10 ± 3 6 ± 3
48 h 11 ± 4 10 ± 3
Intracranial pressure (mmHg)
Baseline 10 ± 6 11 ± 7
24 h 8 ± 5 12 ± 4
48 h 11 ± 4 9 ± 3
TG time–group effect
Fig. 1 Serum sodium concentrations at baseline, 24 and 48 h
Fig. 2 Serum chloride concentrations at baseline, 24 and 48 h
Fig. 3 Serum osmolality at baseline, 24 and 48 h
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day, serum potassium concentrations were similar (saline
group, baseline: 3.8 ± 0.6 mmol/L, 24 h: 3.6 ± 0.3 mmol/
L, and balanced group 3.6 ± 0.5 mmol/L, and 3.5 ± 0.3
mmol/L), and then slightly increased in the balanced group
(to 3.8 ± 0.4 mmol/L, p = 0.020) but not in the saline
group (3.6 mmol/L). Nine (50 %) patients in the saline
group and 8 (44 %) in the balanced group experience
hypokalemia (<3.5 mmol/L). At 24 h, patients receiving
norepinephrine had significantly lower potassium concen-
trations (3.4 ± 0.2 mmol/L) than those who did not
(3.6 ± 0.3 mmol/L, p = 0.041).
Serum creatinine and urea were similar in both groups:
creatinine of group saline versus group balanced was 56 ± 14
vs. 60 ± 20 lmol/L at baseline and 52 ± 11 vs. 54 ± 12
lmol/L (NS) at 48 h. Urea was 5 ± 3 vs. 6 ± 5 mmol/L at
baseline and 4 ± 2 vs. 5 ± 3 mmol/L (NS) at 48 h.
Changes in arterial serum pH and base excess are shown
in Figs. 4 and 5. pH increased in both groups (time effect,
p < 0.012). More patients in the saline group presented
with metabolic acidosis [BE <-2; 12 (67 %) vs. 2
(11 %); p = 0.001].
Changes in cortisol, thyroid-stimulating hormone, free
triiodothyronine, and thyroxine are indicated in Table 4.
Cortisol and fT3 decreased in both study groups.
Urinary electrolytes and osmolality are indicated in
Table 5. Urinary sodium concentrations remained similar
between groups. At 48 h, urine chloride concentrations were
higher in the saline group (132 ± 42 vs. 95 ± 37 mmol/L,
p = 0.034). Differences in urine osmolality and potassium
concentrations were not significant.
Osmolar clearance was similar in the saline and balanced
groups (day 1: 3,900 ± 2,280 vs. 5,900 ± 3,550 mL/day;
day 2: 5,170 ± 2,600 vs. 4,590 ± 2,280 mL/day; NS).
There was also no difference in free water clearance (day 1:
-1,840 ± 1,680 vs. -2,660 ± 2,030 mL/day; day 2: -
2,410 ± 1,500 vs. -1,710 ± 850 mL/day; NS).
Patients with SAH Hunt and Hess grades 3 and 4 tended to
have both lower osmolar and free water clearance compared to
patients with scores 1 and 2 (osmolar clearance day 1:
3,700 ± 1,920 vs. 6,400 ± 3,760 mL/day; p = 0.03; day 2:
7,860 ± 3,560 vs. 13,580 ± 7,370 mL/day; p = 0.06; free
water clearance day 1: -1,960 ± 1,000 vs. -3,030 ±
2,230 mL/day; p = 0.13; day 2: -3,870 ± 1,800 vs.
-6,730 ± 3,380 mL/day; p = 0.05).
Fig. 4 Arterial pH at baseline, 24 and 48 h
Fig. 5 Arterial base excess at baseline, 24 and 48 h
Table 4 Time course of cortisol, TSH, fT3, and fT4
Saline group Balanced group Test, p value
N baseline 18 18
N 24 h 18 16
N 48 h 14 10
Cortisol (nmol/L)
Baseline 1,014 ± 893 793 ± 842 T, 0.047
24 h 540 ± 286 746 ± 476
48 h 543 ± 272 494 ± 281
TSH (mU/L)
Baseline 1.17 (0.2–3.1) 1.36 (0.3–4.9)
24 h 0.81 (0.1–2.5) 0.94 (0.2–2.6)
48 h 0.82 (0.1–2.6) 0.95 (0.2–2.6)
fT3 (pg/mL)
Baseline 3.6 (2.2–5.5) 3.2 (2.0–4.6) T, 0.001
24 h 2.7 (1.8–4.1) 2.9 (1.7–4.1)
48 h 2.3 (1.6–3.1) 2.5 (1.7–3.4) 0.009/0.027a
fT4 (ng/dl)
Baseline 14.8 (9.6–19.7) 15.0 (9–19.2)
24 h 13.7 (8.8–20.4) 14.6 (9.7–18.4)
48 h 12.6 (0.2–19) 14.0 (11.1–24.4)
TSH thyroid-stimulating hormone, fT3 free triiodothyronine, fT4 free
thyroxine, T time effect
a Paired t test per group, 24 vs. 48 h
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Discussion
The main findings of this blinded, randomized study are
that a saline-based infusion regimen was associated with a
higher sodium input compared to sodium excretion during
the first 24 h. More patients had a fluid balance
>1,500 mL during this time, and serum sodium, chloride,
and osmolality increased, and metabolic acidosis was more
frequent compared to the balanced infusion regimen.
Since hyponatremia after SAH may be an independent
risk factor for poor outcome [4, 15], infusions with lower
sodium content than normal saline could theoretically be
harmful. However, uncontrolled prospective studies rather
suggest a relationship between hyponatremia and excessive
natriuresis and volume contraction [16, 17]. Volume con-
traction has been linked to symptomatic vasospasm [18], and
fluid restriction has been associated with an increased inci-
dence of delayed ischemic deficits [16]. In several
uncontrolled studies, the development of volume contraction
was found to be ameliorated by the administration of large
amounts of fluids [17, 19]. In another study, however, only
hyponatremia but not decreased circulating blood volume
was prevented by administration of large amounts of sodium
and water, adapted to renal excretion [20]. The guidelines of
the American Heart Association [21] recommend that vol-
ume contraction be treated with isotonic fluids (Class IIa,
Level of Evidence B), and that ‘‘administration of large
volumes of hypotonic fluids should generally be avoided
after SAH (Class I, Level of Evidence B)’’. Similarly, the
very recently released guidelines of the Neurocritical Care
Society for the management of patients with SAH recom-
mend avoiding large amounts of free water intake and
avoiding fluid restriction to treat hyponatremia [22]. Neither
set of guidelines addresses the composition of baseline fluid
administration in patients without oral intake.
Our data suggest that volume administration using either
hypotonic or isotonic fluids during the first 2 days after SAH
is associated with normal average serum sodium concen-
trations and a large variability in daily fluid balance, despite
an overall increase in central venous blood pressure. Inter-
estingly, while the amount of sodium administration was
similar in both groups, this amount was significantly higher
than sodium excretion during the first 24 h in the saline but
not the balanced group. Since we investigated only a rela-
tively small group of patients, and performed a large number
of statistical comparisons, our results have to be interpreted
with caution. Future studies should record the exact reasons
why fluids are administered in these patients.
During the short observation period in our study, inap-
propriate ADH secretion and cerebral salt wasting syndrome
were not an issue: only two patients presented with a serum
sodium concentration <135 mmol/L, which resolved in
one. In other studies with longer observation periods,
hyponatremia developed frequently after SAH [1, 23] and
was associated with negative sodium balance [1, 24] and
fluid balance [25]. The authors found almost uniformly
increased ANP and/or BNP concentrations and delayed
activation of the renin–aldosterone axis [1, 2, 24]. Unfortu-
nately, we did not measure ANP, BNP, or renin/aldosterone
concentrations, and therefore cannot evaluate their potential
contribution to our findings. Nevertheless, we may speculate
that the numerically lower osmotic clearance in the saline
group during the first day, together with the positive sodium
balance, suggests a shift of the ANP/BNP-aldosterone bal-
ance toward aldosterone in the saline group. Of note,
hypernatremia (sodium concentration >145 mmol/L) was
only present in 3 out of the 18 patients in the saline group.
Normal responses to administration of large amounts of
hypotonic fluids are diminished anti-diuretic hormone
secretion and decreased activation of the renin–angiotensin
axis (unless tubular chloride concentrations become low).
Consequently, one would expect higher free water clear-
ance in the balanced group, which tended to be the case
Table 5 Time course of urinary electrolytes, creatinine, and
osmolality
Saline group Balanced group Test, p value
N baseline
Na/K 14/17 17/17
Cl/Osmolal. 17/16 16/17
N 24 h
Na/K 18/17 17/17
Cl/Osmolal. 18/18 17/16
N 48 h
Na/K 14/10 10/10
Cl/Osmolal. 14/14 10/10
Sodium (Mmol/L)
Baseline 104 ± 49 75 ± 42
24 h 83 ± 59 117 ± 45
48 h 119 ± 45 96 ± 42
Potassium (Mmol/L)
Baseline 52 ± 40 48 ± 32 T, 0.029
24 h 42 ± 14 34 ± 21
48 h 39 ± 31 30 ± 17
Chloride (Mmol/L)
Baseline 100 ± 59 89 ± 55 TG, 0.034
24 h 95 ± 55 120 ± 50
48 h 132 ± 42 95 ± 37 0.032/n.s.a
Osmolality (Mosmol/kg)
Baseline 550 ± 171 562 ± 203
24 h 566 ± 124 563 ± 144
48 h 614 ± 203 535 ± 160
TG time–group interaction, T time effect
a Paired t test per group, 24 vs. 48 h
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during the first 24 h. Divergent alterations in cortisol and/
or thyroid hormone metabolism in the two groups can be
excluded as an alternative explanation, since basal cortisol
and fT3 decreased similarly in both groups and basal TSH
did not change in either group. It seems therefore unlikely
that the administration of corticosteroids to 11 vs. 6
patients in the saline versus balanced group has influenced
our results. Nevertheless, it has been demonstrated that
corticosteroids can influence water and sodium balance
after subarachnoidal hemorrhage [26, 27].
Fluid balance was not associated with arterial hyper-
tension or the use of steroids or norepinephrine. However,
fluid balance was significantly higher in patients with more
severe SAH (Hunt and Hess grades 3 and 4); this was
accompanied by lower osmotic and free water clearances
compared to patients with Hunt and Hess grades 1 and 2,
suggesting again a different profile of ANP, BNP, and
renin/aldosterone between these two patient groups.
Hypokalemia was frequent in both groups and not
explained by the use of diuretics. A high incidence of
hypokalemia in SAH, especially in female patients, has
previously been described [28, 29]. Hypokalemia has been
attributed to stimulation of b-adrenoceptor and activation
of membrane Na+/K+-ATPase [30]. Indeed, in our study,
we found slightly lower serum potassium concentrations in
patients who received norepinephrine during the first 24 h
compared to those who did not.
Myocardial dysfunction is related to the severity of
subarachnoidal hemorrhage [31]. Myocardial dysfunction
may have influenced renal function and water clearance in
our study as well. We measured troponin I only in half of
the patients, and found no differences between groups.
Patients in the two groups had similar lengths of stay in the
ICU and in the hospital, and the occurrence of neurological
deficits was similar between groups after 48 h of treatment.
Likewise, the modified Rankin scale at hospital discharge did
not show differences between groups. Since the distinct
infusion regimens were only maintained for 48 h and the
number of patients in each group was fairly low, outcome was
not our primary endpoint and should be interpreted very
cautiously. Future studies should evaluate effects of different
fluid regimen over a longer time period since the pathophys-
iology of fluid and electrolyte homeostasis and the response to
the respective intervention may change over time in patients
with subarachnoidal hemorrhage.
Conclusions
We conclude that in our small cohort of patients, 48 h of
treatment with saline-based fluids resulted in a greater
number of patients with hyperchloremia, hyperosmolality,
metabolic acidosis, and positive fluid balance >1,500 mL
during the first day. Administration of balanced solutions did
not cause more frequent hyponatremia or hypo-osmolality.
These results should be confirmed in studies including larger
numbers of patients and a longer treatment period.
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